Results 131 to 140 of about 37,848 (274)

Imidazolium‐Based Ionic Liquids as Antifungal and Antibiofilm Agents Against Candida tropicalis

open access: yesChemistrySelect, Volume 11, Issue 4, 28 January 2026.
Candida sp. biofilms, particularly those formed on catheters, represent a major clinical challenge. This study evaluates ionic liquids using an experimental biofilm model, demonstrating significant antifungal activity and biofilm disruption, supporting their potential application as alternative strategies for device‐associated infection control ...
Giovanna de Jesus Agostinetto   +4 more
wiley   +1 more source

Fetal Bradycardia Prompting the Diagnosis and Management of Parental Long QT Syndrome. [PDF]

open access: yesCirc Arrhythm Electrophysiol
Ananthan K   +11 more
europepmc   +1 more source

Risk assessment of drug-induced Long QT Syndrome for some COVID-19 repurposed drugs [PDF]

open access: gold, 2020
Véronique Michaud   +6 more
openalex   +1 more source

Longitudinal Profiling of DNA Methylation Reveals Age‐Varying CpG Sites and Novel Insights Into Aging Heterogeneity

open access: yesAging Cell, Volume 25, Issue 1, January 2026.
We longitudinally profiled DNA methylation in 135 relatively healthy older adults from the RLAS study, identifying 3145 CpG sites exhibiting increasing inter‐individual variability with age and 125,353 sites exhibiting significant changes in average methylation levels with age.
Xueqing Jia   +11 more
wiley   +1 more source

Cardiovascular safety of testosterone therapy—Insights from the TRAVERSE trial and beyond: A position statement of the European Expert Panel for Testosterone Research

open access: yesAndrology, Volume 14, Issue 1, Page 294-302, January 2026.
Abstract Introduction Testosterone therapy has become a cornerstone treatment for men with hypogonadism, offering significant benefits such as improved sexual function, mood, muscle mass, and bone density. However, concerns about its cardiovascular safety have historically tempered its use.
Michael Zitzmann   +15 more
wiley   +1 more source

Benefits of Implantable Cardioverter–Defibrillator for Secondary Prevention in Patients With Organic Heart Disease

open access: yesAnnals of Noninvasive Electrocardiology, Volume 31, Issue 1, January 2026.
Three‐quarters of patients who underwent ICD/CRT‐D implantation for secondary prevention received appropriate ICD therapy and survived at least 1 year thereafter. In contrast, patients aged 70 or older and those with a history of ventricular fibrillation (VF) were less likely to benefit from secondary prevention with an ICD.
Rie Akagawa   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy